What's Happening?
Kaplan Fox & Kilsheimer LLP, a national law firm specializing in complex litigation, has announced an investigation into Corcept Therapeutics, Inc. for potential securities law violations. This follows a significant drop in Corcept's stock price after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the company's New Drug Application (NDA) for relacorilant. The FDA's letter indicated that it could not approve the drug for treating hypertension secondary to hypercortisolism without additional evidence of its effectiveness. As a result, Corcept's stock price fell by more than $37 per share, over 50%, during intraday trading on December 31, 2025. Kaplan Fox is reaching out to investors who have suffered
losses to potentially join the investigation.
Why It's Important?
The investigation by Kaplan Fox could have significant implications for Corcept Therapeutics and its investors. If the law firm finds evidence of securities law violations, it could lead to legal action against the company, potentially resulting in financial penalties or settlements. This situation underscores the importance of transparency and compliance with regulatory standards in the pharmaceutical industry. For investors, the outcome of this investigation could affect their financial interests, especially if they have experienced losses due to the stock price drop. The case also highlights the critical role of the FDA in ensuring that new drugs meet safety and efficacy standards before approval.
What's Next?
As the investigation progresses, Kaplan Fox will likely gather more information and evidence to determine whether Corcept Therapeutics violated securities laws. Investors who have suffered losses are encouraged to contact the law firm to discuss their options. Depending on the findings, Kaplan Fox may file a lawsuit on behalf of affected investors. Meanwhile, Corcept Therapeutics may need to address the FDA's concerns by providing additional evidence of relacorilant's effectiveness to potentially resubmit their application. The company's response to the FDA's feedback and the outcome of the investigation will be closely watched by investors and industry analysts.
